Total
0
Shares
Source: Cann Global
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cann Global’s (CGB) joint venture partner, Canntab Therapeutics, has been granted an Australian patent in relation to its proprietary immediate release cannabidiol formulations
  • The partners formed a 50:50 joint venture in 2018 to bring Canntab’s range of hard oral dose cannabinoid tablets to Australia
  • Cann Global has placed an initial C$406,200 (approximately A$418,000) order for six products which will be filled when Cantabb receives an export permit
  • Once the products arrive in the country, the range will be made available through the Special Access Scheme B, Authorised prescriber schemes as well as the Cannabinoid Medicine Observational Study
  • CGB shares are up 6.25 per cent to 0.9 cents

Cann Global’s (CGB) Canada-based joint venture partner, Canntab Therapeutics, has been granted an Australian patent.

The patent, No. AU 2018210690, was granted in relations to Canntab’s proprietary immediate release cannabidiol formulations. The patent has a priority date of January 23, 2017, and expires on January 22, 2038.

Cann Global and Canntab formed a 50:50 joint venture partnership in 2018 with the objective of bringing a range of hard pill cannabinoid formulations to Australia.

Once the products arrive in the country, the range will be made available through the Special Access Scheme B, Authorised prescriber schemes as well as the Cannabinoid Medicine Observational Study (CMOS).

The study is the largest observational study for cannabinoid medicines undertaken to date in the country and will evaluate the safety and efficacy of medicinal cannabis products.

The CMOS aims to enrol 20,000 patients with conditions such as fibromyalgia, chronic pain syndromes, PTSD and epilepsy and will collect data on health-related outcomes.

Cann Global has already placed an initial C$406,200 (approximately A$418,000) order for six products from the Canntab range: two THC products, two CBD products and two THC/CBD blends. 

Cann Global has received an import permit for the products, while Canntab awaits an export permit from Health Canada.

CGB shares are up 6.25 per cent to 0.9 cents at 10:26 am AEDT.

CGB by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.